Subtle Medical的动态

So exciting, unlimited potential

An ingestible robot that can diagnose stomach cancer? Sounds like something straight out of a sci-fi thriller, right? That was my exact reaction when I first read about Endiatx’s groundbreaking PillBot. PillBot is the first disposable, remote-controlled endoscopy pill, offering a more convenient, patient-friendly alternative to traditional upper GI endoscopies. By eliminating the need for clinic visits and anesthesia, it aims to expand access to care. Currently in clinical trials, PillBot aims for FDA clearance in 2025 and a US launch in 2026. But that's not all. The company has big plans to integrate artificial intelligence into the PillBot’s diagnostic capabilities to minimize the need for human intervention. As cool as this sounds (and a little creepy, like something from Alien), I can't help but be intrigued. Will PillBot be the game-changer in GI endoscopy, or will it be another over-hyped gadget that fizzles out? I’m keeping a close eye on the trial results. Stay tuned! ??

?? How do we work on medical imaging algorithms that are tailored to our customer's specific needs? We are often asked this question. We've built a powerful pipeline that streamlines the process. This translates to faster delivery and more tailored solutions for our valued partners. Read more: ?? https://lnkd.in/d2_KYiR3 #medicalimaging #medicalalgorithm

The future of pathology is here, and it's digital! OptraSCAN is reshaping the way we approach diagnostics, moving beyond the limitations of traditional methods. Imagine automated whole slide imaging that cuts diagnosis time by 40%, AI-driven analysis that eliminates human error, and seamless global collaboration from anywhere in the world. With #OptraScan, physical #storage, degradation risks, and manual handling are replaced with secure digital storage and rapid retrieval, ensuring you’re always ahead. Our scalable solutions grow with your needs, making us the partner for labs ready to embrace the future of pathology. Discover how OptraScan is setting new standards in #accuracy, #efficiency, and #collaboration. Step into the future of #pathology with OptraSCAN. From #AI-powered #diagnostics to #globalcollaboration, we’re transforming #healthcare one slide at a time. #DigitalPathology #OptraScan #AIinHealthcare #PathologyInnovation #WholeSlideImaging

D’Ornano + Co. advised Left Lane Capital in leading Pearl $58M Series B. Los Angeles-based Pearl leverages AI to enhance dental care by providing automated, accurate diagnostic tools and patient care solutions. Pearl has made history by securing the first-ever FDA clearance for AI software designed to support dental professionals. Since its inception in 2019, Pearl has revolutionized dental care, with its cutting-edge products now empowering over 500,000 dental centers across more than 120 countries. The company plans to utilize the funding to accelerate the development of its computer vision technology, enhancing capabilities like disease detection and 3D tracking, and to launch new AI tools. A D’Ornano + Co. team composed of Raphaelle d'Ornano, Marie-céline Kauff, Bruno du Breuil and Thomas Huet was delighted to work alongside lead investor Left Lane Capital to provide insights on Pearl’s growth and profitability perspectives. Read more on Business Wire: https://urlr.me/GN1Sv #Latestage #VC #VerticalSaaS #AIML

What if a platform existed to help doctors make faster more accurate diagnoses? INDEX intends to create a high-quality medical imaging platform that does not currently exist to benefit the entire imaging ecosystem. https://lnkd.in/eNgzgBt9

Synapse 3D is an advanced image visualization solution, which is part of its Synapse Enterprise Imaging portfolio. Synapse 3D is designed to address six key challenges in medical imaging: integrity, scalability, productivity, demand for effective applications, inherent cardiology support, and the need for innovation in a rapidly evolving healthcare environment. Synapse 3D offers over 50 applications tailored to different clinical needs, facilitating efficient, collaborative workflows with features like server-side rendering, zero-click preprocessing, and customizable settings. Additionally, the platform is AI-ready, with support for advanced capabilities like computer-aided detection, workflow prioritization, and organ region recognition. #Synapse3d #Fujifilm https://lnkd.in/gENhec6m

Access to large, affordable, high-quality and representative datasets is one of the most significant challenges faced by AI/ML developers today. The ARPA-H ImagiNg Data EXchange (INDEX) program aims to create a platform that seamlessly links data providers, data users, and service providers with high quality and affordable images that will enable robust, trustworthy AI tool development for pathology and radiology in collaboration with the U.S. Food and Drug Administration (FDA) Office of Science and Engineering Laboratories (OSEL) in the Center for Devices and Radiological Health (CDRH) ARPA-H will host a Proposer’s Day on January 9. Proposer’s Day sign up: https://lnkd.in/eWYK9meG Program details: https://lnkd.in/eHwSXCV3 3 Technical areas: - Business model and business plan - System architecture design and implementation - Enrollment

DICOM is really important for the aceptance of digital pathology

The post-processing applications are game changers for surgery planning, helping surgeons/clinicians visualize complex structures and make informed decisions with greater confidence. Synapse 3D offer over 50 applications tailored to different clinical needs. Proud to be part of a team pushing the boundaries of healthcare technology! ?? #Synapse3D #MedicalImaging #SurgeryPlanning #PrecisionMedicine"